Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

Aine McKillop, NA Duffy, JR Lindsay, BD Green, Steven Patterson, Finbarr O'Harte, PM Bell, Peter Flatt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P
LanguageEnglish
Pages877-885
JournalEuropean Journal of Endocrinology
Volume16
Issue number6
DOIs
Publication statusPublished - 15 Sep 2009

Fingerprint

nateglinide
Dipeptidyl Peptidase 4
Glucose
Peptides
Hyperglycemia
Cross-Over Studies
Type 2 Diabetes Mellitus
Oral Administration
Fasting
Research Design
Placebos
Insulin
Control Groups

Cite this

@article{934f8404294a4488a5366e62f26c9899,
title = "Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.",
abstract = "BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P",
author = "Aine McKillop and NA Duffy and JR Lindsay and BD Green and Steven Patterson and Finbarr O'Harte and PM Bell and Peter Flatt",
year = "2009",
month = "9",
day = "15",
doi = "10.1530/EJE-09-0547",
language = "English",
volume = "16",
pages = "877--885",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
number = "6",

}

TY - JOUR

T1 - Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

AU - McKillop, Aine

AU - Duffy, NA

AU - Lindsay, JR

AU - Green, BD

AU - Patterson, Steven

AU - O'Harte, Finbarr

AU - Bell, PM

AU - Flatt, Peter

PY - 2009/9/15

Y1 - 2009/9/15

N2 - BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P

AB - BACKGROUND: Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design. RESULTS: Plasma glucose reached 18.2+/-1.7 and 16.7+/-1.7 mmol/l at 90 min in control and placebo groups (P

U2 - 10.1530/EJE-09-0547

DO - 10.1530/EJE-09-0547

M3 - Article

VL - 16

SP - 877

EP - 885

JO - European Journal of Endocrinology

T2 - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 6

ER -